Novartis' Sandoz splurges on a trio of GSK antibiotics, doubling down with a $500M bet on a field struggling to combat resistant microbes
Most major drugmakers over the past few years have fled the antibiotics space, which has been doubly hit by resistant “super bugs” and scarce innovation. Novartis was one of those R&D evacuees, hitting the eject button back in 2018, but on the generic antibiotics front it’s still hanging in there and even adding to its portfolio.
Sandoz will shell out $350 million upfront and an additional $150 million in downstream milestones for three of GSK’s cephalosporin antibiotics, most notably Zinnat, the Swiss generics maker said Thursday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.